Article Text

Download PDFPDF
Charles Bonnet syndrome and brimonidine: comments
  1. I Rahman,
  2. B Fernando,
  3. M Harrison
  1. Manchester Royal Eye Hospital, Lister Centre, Nelson Street, Manchester M1, UK
  1. Correspondence to: MrImran Rahman Manchester Royal Eye Hospital, Lister Centre, Nelson Street, Manchester M1, UK; imran1973tiscali.co.uk

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read, with interest the article published in the BJO by Tomsak et al.1 Interest in the Charles-Bonnet syndrome (CBS) has escalated of late, highlighting the probable 15% incidence of the condition in patients with significant visual impairment coupled with a clear sensorium.2

The authors implied that CBS was induced in four patients by brimonidine tartrate on the basis of patient age and the instigation of brimonidine therapy, with discontinuation resulting in eventual resolution of the hallucinations. Firstly, the diagnostic criteria proposed by Gold and Rabins3 and Podell et al,4

View Full Text